Xencor, in an updated on phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, said data from early-stage studies suggested that PD-1 and CTLA-4 inhibition has promise in prostate cancer, an area with high unmet need and without much checkpoint use.
The company has observed vudalimab to be generally well tolerated, with lower rates of some types of immunotherapy-related adverse events, and to have encouraging clinical activity, Xencor said in a statement.
The company said it is now enrolling a phase 2 study of vudalimab for patients with metastatic castration-resistant prostate cancer, as a monotherapy or in combination, depending on molecular subtype.
In addition, the company is initiating a second Phase 2 study in patients with advanced pelvic tumors, including clinically defined high risk mCRPC and certain gynecologic malignancies.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.